| HOME >> BIOLOGY >> TECHNOLOGY |
$
20,198Restricted cash702
0Accounts receivable, net42,496
30,437Royalty income receivable8,180
6,819Inventory28,216
26,004Total current assets113,424
100,560Restricted cash4,524
0Property and equipment, net135,519
149,796Total assets262,862
263,067Total current liabilities35,986
37,976Long‑term debt, excluding current installments7,227
3,003Total liabilities56,721
56,633Total stockholders' equity206,141
206,434Total liabilities and stockholders' equity262,862
263,067
Table 1: Reconciliation of fourth quarter and full year 2012 and 2011 reported income (loss) from operations, net income (loss) and earnings (loss) per diluted share to adjusted income (loss) from operations, adjusted net income (loss) and adjusted earnings (loss) per share:Fourth Quarter
2012Fourth Quarter
2011YTDDecember 31,
2012YTDDecember 31,
2011Income (loss) from operations, as reported$
2,254$
(27,327)$ 703$ (36,132)Impairment charges4,36721,3428,27521,342Restructuring charges8893204,6321,271Executive transition costs396-1,397-FDA remediation costs231723632Arbitration charges---127Real property tax credit adjustment---375Income (loss) from operations, as adjusted7,929$
(5,648)$
5,030$
(12,385)Net income (loss), as reported$
,916$
(24,409)$ (3,777)$
(32,296)Adjustments, net of tax where applicable:Impairment charges2,83918,4666,70918,466Restructuring charges6092084,166835Executive transition costs257-908-FDA remediation costs(166)(73)(182)327Arbitration charges---83Real property tax credit adjustment---245Settlement of acquisition related contingen
'/>"/>
| SOURCE AMRI Copyright©2012 PR Newswire. All rights reserved |